Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies

Journal of Pharmaceutical Policy and Practice

Volumn 8, Issue 1, 2015, Pages 1-9

  Hsu, Jason C ^a   Ross Degnan, Dennis ^b   Wagner, Anita K ^b   Cheng, Ching Lan ^a   Yang, Yea Huei Kao ^a   Zhang, Fang ^b   Lu, Christine Y ^b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chronic medication prescriptions; Interrupted time series; Oral antidiabetic medications; Taiwan

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; GUAR GUM; LIRAGLUTIDE; MITIGLINIDE; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ARTICLE; CHRONIC DISEASE; DIABETES MELLITUS; DRUG UTILIZATION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH PROMOTION; HUMAN; NATIONAL HEALTH INSURANCE; OUTPATIENT CARE; PHARMACY; PRESCRIPTION; PUBLIC HEALTH; REIMBURSEMENT; TAIWAN; TIME SERIES ANALYSIS; TREND STUDY;

EID: 84983156842     PISSN: None     EISSN: 20523211     Source Type: Journal    
DOI: 10.1186/s40545-015-0035-5     Document Type: Article

References (44)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med. 1997; 14 Suppl 5: S1-85.
2. Boyc KS, Yurgin N, Lage MJ. Trends in the prescription of antidiabetic medications in France: evidence from primary care physicians. Adv Ther. 2007; 24: 803-13.
3. Mazzaglia G, Yurgin N, Boye KS, et al. Prevalence and antihyperglycemic prescribing trends for patients with type 2 diabetes in Italy: a 4-year retrospective study from national primary care data. Pharmacol Res. 2008; 57: 358-63.
4. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414: 782-7.
5. Walley T, Hughes D, Kendall H. Trends and influences on use of antidiabetic drugs in England, 1992-2003. Pharmacoepidemiol Drug Saf. 2005; 14: 769-73.
6. Baviera M, Monesi L, Marzona I, Avanzini F, Monesi G, Nobili A, et al. Trends in drug prescriptions to diabetic patients from 2000 to 2008 in Italy's Lombardy Region: a large population-based study. Diabetes Res Clin Pract. 2011; 93: 123-30.
7. Patel H, Srishanmuganathan J, Car J, Majeed A. Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004. J Public Health (Oxf). 2007; 29: 48-52.
8. WHO. (website: http: //www. who. int/diabetes/en/).
9. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27: 1047-53.
10. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87: 4-14.
11. Taiwan Health Promotion Administration, Ministry of health and Welfare, Prevalence of chronic diseases (website: website: http: //www. hpa. gov. tw/ BHPNet/Web/HealthTopic/TopicArticle. aspx?No=201410030002&parentid= 201409290001)
12. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Diabetes Care. 1995; 18: 1050-64.
13. O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ. Direct medical costs of complications resulting from type 2 diabetes in the U. S. Diabetes Care. 1998; 21: 1122-8.
14. Cohen FJ, Neslusan CA, Conklin JE, Song X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003; 26: 1847-51.
15. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care. 2003; 26: 1852-5.
16. Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf. 2009; 18: 973-6.
17. Rathmann W, Haastert B, Icks A, Giani G. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004. Diabetes Care. 2007; 30: 848-53.
18. Doro P, Benko R, Kosik E, Matuz M, Toth K, Soos G. Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy. Eur J Clin Pharmacol. 2005; 61: 893-7.
19. Chiang CW, Chiu HF, Chen CY, Wu HL, Yang CY. Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003. J Clin Pharm Ther. 2006; 31: 73-82.
20. National Health Insurance Administration (website: http: //www. nhi. gov. tw/ AmountInfoWeb/iDesc. aspx?rtype=2&Q5C2_ID=889)
21. Taiwan Ministry of Health and Welfare, National Health Insurance Act. 2011 (website: http: //mohwlaw. mohw. gov. tw/Chi/EngContent. asp?msgid=279& KeyWord=%A5%FE%A5%C1%B0%B7%B1d%ABO%C0I)
22. Ho YF, Hsieh LL, Lu WC, et al. Appropriateness of ambulatory prescriptions in Taiwan: translating claims data into initiatives. Int J Clin Pharm. 2012; 34: 72-80.
23. Rachel Lu JF, Chiang TL. Evolution of Taiwan's health care system. Health Econ Policy Law. 2011; 6: 85-107.
24. Taiwan National Health Insurance adminisatration (website: http: // www. nhi. gov. tw/webdata/webdata. aspx?menu=17&menu_id= 1028&webdata_id=1391)
25. National Health Research Institute, National Health Insurance Reseach Database (website: http: //nhird. nhri. org. tw/brief_01. htm) (accessed 8 June, 2011).
26. Liu SZ, Romeis JC. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly. Med Care. 2003; 41: 1331-42.
27. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27: 299-309.
28. Lu CY, Ross-Degnan D, Stephens P, Liu B, Wagner AK. Changes in use of antidiabetic medications following price regulations in China (1999-2009). J Pharm Health Serv Res. 2013; 4: 3-11.
29. Lu CY, Zhang F, Lakoma MD. Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ. 2014; 348: g3596.
30. Hsu JC, Lu CY, Wagner AK, Chan KA, Lai MS, Ross-Degnan D. Impacts of drug reimbursement reductions on utilization and expenditures of oral antidiabetic medications in Taiwan: an interrupted time series study. Health Policy. 2014; 116: 196-205.
31. Lu CY, Soumerai SB, Ross-Degnan D, Zhang F, Adams AS. Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Med Care. 2010; 48: 4-9.
32. Serumaga B, Ross-Degnan D, Avery AJ, et al. Effect of pay for performance on the management and outcomes of hypertension in the United Kingdom: interrupted time series study. BMJ. 2011; 342: d108.
33. Shadish WCT, Campbell D. Experimental and quasi-experimental designs for generalized causal inference Houghton Mifflin. 2002.
34. Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol. 2009; 62: 143-8.
35. Index Mundi, Demographics of Taiwan population. 2014 (website: http: //www. indexmundi. com/taiwan/population. html)
36. Taitel M, Fensterheim L, Kirkham H, Sekula R, Duncan I. Medication days' supply, adherence, wastage, and cost among chronic patients in Medicaid. Medicare Medicaid Res Rev. 2012; 2(3): E1-13.
37. Wang JY, Lee SH, Lee IT, Chen JD, Sheu WH. Effect of prescription refill on quality of care among patients with type 2 diabetes: an exploratory study. Diabetes Res Clin Pract. 2014; 105: 110-8.
38. Berenguer B, La Casa C, de la Matta MJ, Martin-Calero MJ. Pharmaceutical care: past, present and future. Curr Pharm Des. 2004; 10: 3931-46.
39. Pringle JL, Boyer A, Conklin MH, McCullough JW, Aldridge A. The pennsylvania project: pharmacist intervention improved medication adherence and reduced health care costs. Health Aff (Millwood). 2014; 33: 1444-52.
40. Munoz EB, Dorado MF, Guerrero JE, Martinez FM. The effect of an educational intervention to improve patient antibiotic adherence during dispensing in a community pharmacy. Aten Primaria. 2014; 46: 367-75.
41. Williams J, Steers WN, Ettner SL, Mangione CM, Duru OK. Cost-related nonadherence by medication type among Medicare Part D beneficiaries with diabetes. Med Care. 2013; 51: 193-8.
42. Kurlander JE, Kerr EA, Krein S, Heisler M, Piette JD. Cost-related nonadherence to medications among patients with diabetes and chronic pain: factors beyond finances. Diabetes Care. 2009; 32: 2143-8.
43. Laba TL, Lehnbom E, Brien JA, Jan S. Understanding if, how and why non-adherent decisions are made in an Australian community sample: a key to sustaining medication adherence in chronic disease? Res Social Adm Pharm. 2015; 11: 154-62.
44. Hsu JC, Lu YC. The evolution of Taiwan's National Health Insurance drug reimbursement scheme. DARU J Pharma Sci 2015; 23(15) (website: http: // www. ncbi. nlm. nih. gov/pmc/articles/PMC4333892/)